Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grape King BioTPE:1707 -1.73%79 Return-on-Tangible-Equity is 17.55% as of Dec. 2025, which is 4% below its 10-year median of 18.37. GuruFocus rates TPE:1707 with a GF Score™ of 79/100 and a GF Value™ of NT$144.12 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 900 Drug Manufacturers companies, Grape King Bio ranks better than 63.33% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Grape King Bio's annualized net income for the quarter that ended in Dec. 2025 was NT$1,779 Mil. Grape King Bio's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$10,138 Mil. Therefore, Grape King Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 17.55%.
The historical rank and industry rank for Grape King Bio's Return-on-Tangible-Equity or its related term are showing as below:
TPE:1707'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 12.08 Med: 18.37 Max: 31.45
Current: 12.32
During the past 13 years, Grape King Bio's highest Return-on-Tangible-Equity was 31.45%. The lowest was 12.08%. And the median was 18.37%.
TPE:1707's Return-on-Tangible-Equity is ranked better than 63.33% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs TPE:1707: 12.32
Grape King Bio (TPE:1707) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Grape King Bio Return-on-Tangible-Equity Related Terms
Grape King Bio Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1707 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.55% mean?
Grape King Bio (TPE:1707) has a Return-on-Tangible-Equity of 17.55% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Grape King Bio and its competitors. This is near median its historical median of 18.37. Over the past decade, Grape King Bio's Return-on-Tangible-Equity has ranged from 12.08 to 31.45. According to the industry distribution chart, Grape King Bio ranks #330 out of 900 companies in the Drug Manufacturers industry, placing it in the top 36.7%.
Is Grape King Bio's Return-on-Tangible-Equity too high?
Grape King Bio's current Return-on-Tangible-Equity of 17.55% is near median its 10-year median of 18.37. Over the past 10 years, this metric has ranged from a low of 12.08 to a high of 31.45. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. Grape King Bio's value of 17.55% is 121.5% above this industry median. Based on the distribution chart, Grape King Bio ranks #330 out of 900 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #330 out of 900 companies for Return-on-Tangible-Equity. This puts Grape King Bio in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.93. Grape King Bio's value of 17.55% is 121.5% above this benchmark. Historically, Grape King Bio's own Return-on-Tangible-Equity has ranged from 12.08 to 31.45 over the past decade. While the company's 10-year median is 18.37 vs. the industry median of 7.93, Grape King Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Return-on-Tangible-Equity of 17.55% is 121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Return-on-Tangible-Equity is 17.55%, which is near median its own 10-year median of 18.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.12, compared to a current price of NT$90.90 — trading 36.9% below its estimated fair value. The current Return-on-Tangible-Equity is 17.55%, which is near median its 10-year median of 18.37 and 121.5% above the Drug Manufacturers industry median of 7.93. Grape King Bio's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Return-on-Tangible-Equity is 17.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$90.90 is trading 36.9% below its estimated GF Value™ of NT$144.12.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
Return-on-Tangible-Equity: 17.55% (near median its 10-year median of 18.37)
GF Value™: NT$144.12 vs. price of NT$90.90 (36.9% below fair value)
Industry Position: 121.5% above the Drug Manufacturers median (#330 of 900)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score
Get the complete analysis for TPE:1707
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
